Greenly CEO Laetitia Carle on the encounters that shaped her path
Laetitia Carle, managing director of carbon-accounting startup Greenly, looks back on the meetings that shaped her career in a new interview filmed at the Stade de France.

Laetitia Carle, managing director of Greenly, says a single encounter can change an entire career. The head of the French startup, which helps companies measure and reduce their carbon footprint, is the latest guest in the interview series "Aux Premières Loges".
The conversation was filmed backstage at the Stade de France, a venue chosen because it is a place built for gatherings. The setting fits the theme of the episode: the people and moments that led Carle to the top of one of France's best-known climate-focused tech companies.
What the interview covers
Two topics run through the discussion. The first is the series of encounters that marked Carle's professional journey and, in her telling, pushed her trajectory in new directions. The second is a principle about entrepreneurship: why a good venture is never forced.
The format is deliberately personal. Rather than a classic product or funding discussion, the episode puts the focus on the individuals who shape the tech ecosystem, and on the choices and relationships behind their careers.
Why it matters
Greenly works in a field where demand from businesses to quantify and cut emissions keeps growing, and leadership profiles like this one offer a look at how the people running such companies got there. Carle's emphasis on timing and relationships, rather than forcing an outcome, is a useful counterpoint to the usual startup narrative of relentless acceleration.
The episode is part of an ongoing series that invites founders and executives to speak candidly about their paths. Further details of what Carle says are in the full video interview.
More from this day
See all →
Proxima Fusion signs Japanese deals with Fujikura and Kyoto Fusioneering

Ex-UK minister Bim Afolami raises £4.9M for AI broker i23

ALLOX Raises $10.5M Seed to Scale AI Drug Discovery Platform
